Autolus Therapeutics Shares Jump After Cancer-Collaboration Agreement with Bristol Myers

 Shares of Autolus Therapeutics Ltd. on Tuesday rose 14% after the U.K. leukemia drug maker announced the signing of collaboration agreement for the treatment of cancer with pharmaceutical company Bristol Myers Squibb Co.

In premarket trading, the stock was up $2.49 after it closed at $2.18 Monday. The shares have fallen more than 50% so far this year.

The biopharmaceutical will receive an upfront payment from Bristol Myers, with the potential to exercise option fees, development milestone payments and royalties, the company said without disclosing details.

Through the agreement, Autolus said it will grant Bristol Myers access to its Rituximab Safety Switch RQR8 to develop a selection of cell therapy programs for the treatment of cancer.

Bristol Myers will have the option to incorporate the RQR8 safety switch in additional cell therapy programs beyond the initial set of selected programs, the company said.

https://www.marketscreener.com/quote/stock/AUTOLUS-THERAPEUTICS-PLC-44336207/news/Autolus-Therapeutics-Shares-Jump-After-Cancer-Collaboration-Agreement-with-Bristol-Myers-41924629/

Immuron in Travelan Clinical Trial Agreement with US-based Pharmaron

 

• Clinical Trial Master Service Agreement with US-based Pharmaron Executed

• Investigational New Drug (IND) application to be submitted to the U.S. Food and Drug administration (FDA)

• Plans in place to initiate a Controlled Human Infection Model (CHIM) clinical trial in 60 healthy volunteers in the USA

• Clinical Trial to examine a dosing regimen for Travelan more suited for use by the US military

• Infectious diarrhea is the most common illness reported by travelers

https://finance.yahoo.com/news/immuron-executes-travelan-clinical-trial-100000838.html

Immutep Fast Tracked for Non-Small Cell Lung Cancer Therapy

• Fast Track designation has been granted by the US FDA for efti in combination with pembrolizumab in 1st line non-small cell lung cancer

• Based on the encouraging Phase II clinical data for PD-L1 all-comers presented at ASCO 2022

• Marks the second Fast Track designation issued by the FDA for eftilagimod alpha, offering the potential for expedited development and review

https://finance.yahoo.com/news/immutep-receives-fda-fast-track-120000746.html

 

Cue Biopharma Fast Tracked for Treatment of Head and Neck Carcinoma

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics designed to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CUE-101, its lead clinical drug candidate from the CUE-100 series of interleukin 2 (IL-2)-based biologics, for the treatment of patients with human papilloma virus (HPV16+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) as a monotherapy and in combination with pembrolizumab (KEYTRUDA®).

https://finance.yahoo.com/news/cue-biopharma-granted-fda-fast-120000424.html

Vir Biotech gets U.S. funding for flu-prevention antibody

 Vir Biotechnology Inc said on Tuesday it had received $55 million in funding from the U.S. government to support its influenza-focused antibody drug that is expected to enter mid-stage trials this year.

The multi-year contract with Biomedical Advanced Research and Development Authority (BARDA) also allows for potential investment of up to $1 billion by the government for developing candidates against emerging infectious disease, including influenza.

The company developed a COVID-19 antibody drug, sotrovimab, along with GSK plc during the pandemic. The BARDA contract will help prepare against future pandemics, Vir Chief Executive Officer George Scangos said.

https://finance.yahoo.com/news/vir-biotech-gets-u-funding-120002522.html

DexCom launches CGM system in Europe, Hong Kong

 

• People with diabetes in the United Kingdom, Ireland, Germany, Austria and Hong Kong can get started with Dexcom G7 now

• The new CGM system is also expected to launch in New Zealand and South Africa in the weeks ahead, with additional markets planned soon after

• A global, streaming launch event held today revealed an inside look at Dexcom G7 through the eyes of company leadership, the G7 project team and Dexcom Warriors from around the world

• Dexcom G7 has the fastest sensor warmup on the market,* with no finger sticks† or scanning required, and builds on the unparalleled accuracy of Dexcom CGM1 that is supported by more peer reviewed, clinical research than any other CGM

https://finance.yahoo.com/news/dexcom-g7-launches-united-kingdom-070000240.html

Pfizer: Positive Topline Results from Phase 3 Prostate Cancer Trial

 

• TALZENNA® first PARP inhibitor to demonstrate clinical benefit in combination with XTANDI® in metastatic castration-resistant prostate cancer (mCRPC)

• Study achieves primary endpoint of radiographic progression-free survival

• Robust, highly consistent efficacy demonstrated in mCRPC both with or without homologous recombination repair gene mutations

https://finance.yahoo.com/news/pfizer-announces-positive-topline-results-104500391.html